-
Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'
Tuesday, June 24, 2025 - 3:06am | 899Hims & Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant. Check out the current price of HIMS...
-
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Monday, November 4, 2024 - 3:54am | 548Novo Nordisk A/S (NYSE:NVO) is advancing its research on a pioneering hybrid drug, CagriSema. This drug merges semaglutide and cagrilintide and aims to reduce weight by 25% without added side effects. What Happened: The Danish pharmaceutical giant is contending with rivals like Eli Lilly & Co...
-
Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity'
Wednesday, October 23, 2024 - 8:23pm | 608Novo Nordisk (NYSE:NVO) has appealed to the U.S. Food and Drug Administration (FDA) to halt the production of compounded versions of its drugs Wegovy and Ozempic by compounding pharmacies. These cheaper alternatives have been under scrutiny due to potential safety risks and lack of FDA approval....
-
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Thursday, September 5, 2024 - 1:17pm | 548Criminals are distributing fake versions of the weight-loss drug Ozempic by forging the drug batch numbers pharmaceutical companies use to authenticate drugs and track them in a specified country. They obtain batch numbers illicitly through a liaison who works at a drugmaker factory or by buying...
-
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
Thursday, May 30, 2024 - 3:36pm | 641The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). These two companies are at the forefront of the burgeoning...
-
Ozempic, Wegovy Lowers Risk Of Cannabis Use Disorder Says New Study
Thursday, March 21, 2024 - 7:08pm | 467People prescribed Ozempic or Wegovy are less likely to develop a cannabis use disorder or relapse from the condition than those who take other diabetes or obesity medications, reported the NewScientist on Thursday. As brand names for the compound semaglutide, Ozempic and Wegovy are said to reduce...
-
Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF?
Tuesday, November 21, 2023 - 9:55am | 651Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and conditions associated with obesity and diabetes, including Novo Nordisk, maker of the blockbuster diet drug Ozempic. The Tema Cardiovascular and Metabolics...
-
'AI' Crowned 2023's Word Of The Year, Nudges Out Greedflation, Deinfluencing
Wednesday, November 1, 2023 - 2:47pm | 539The year 2023 has had its share of themes and innovations, but perhaps none have been as impactful as the rise of artificial intelligence. The choice of “AI” as the word of the year by a leading dictionary is unsurprising to many, given its enduring relevance. What Happened: Much like...
-
Obesity Drug Wegovy Sales Jump 365% In H1 As Novo Nordisk Reports Solid Results, Raises FY23 Guidance
Thursday, August 10, 2023 - 3:49am | 458Danish pharma giant Novo Nordisk A/S (NYSE:NVO) reported a strong increase in first-half sales and profits and also hiked its guidance for the full year for the second time this year. What Happened: Novo Nordisk said its net sales for the first half of the year climbed 29% year-over-year to 107.67...
-
Shortage Of Elon Musk-Popularized 'Miracle' Weight-Loss Drug Puts Diabetic Patients In Peril, Regulator Warns
Tuesday, July 18, 2023 - 10:25pm | 422The demand for the weight-loss drug semaglutide, used by celebrities like Elon Musk and Jeremy Clarkson, is causing a national shortage in the U.K., putting the lives of diabetics at risk, The Daily Mail reports. Off-Label Prescribing Fuels Shortage: The drug, marketed as Ozempic and used for...
-
Raven-Symoné Criticizes Hollywood's Misuse Of Ozempic For 'Glamazon' Purposes: 'Save Some Medication For The People That Actually Need It'
Thursday, July 13, 2023 - 5:51am | 344Actress Raven-Symoné has voiced her concerns about the misuse of the Type 2 diabetes drug Ozempic for weight loss purposes in Hollywood, PopCulture reports. “I think it’s very important we understand certain medications are made for certain people and to not take that away just for...
-
Beware! Ozempic Has A Doppelganger And It Can Be Dangerous
Wednesday, July 12, 2023 - 10:10pm | 494Novo Nordisk (NYSE:NVO), the pharmaceutical giant behind popular semaglutide drugs like Ozempic, Rybelsus, and Wegovy, is making a significant legal push to prevent the sale of semaglutide knockoffs in the U.S., Rolling Stone reports. Legal Battle Against Knockoffs According to the lawsuits...
-
Jessica Simpson Hits Back On Ozempic Weight Loss Rumors: 'I Am Connected To Myself...It Doesn't Mean That It Doesn't Hurt'
Thursday, July 6, 2023 - 10:29pm | 543Jessica Simpson has refuted rumors suggesting that her significant weight loss was due to the controversial diabetes drug, Ozempic, NZ Herald reports. Denial of Ozempic Use In an interview with Bustle, Simpson denied using Ozempic, a drug known for its weight loss-inducing tendencies and popularity...
-
Jessica Simpson Hits Back On Ozempic Weight Loss Rumors: 'I Am Connected To Myself...It Doesn't Mean That It Doesn't Hurt'
Thursday, July 6, 2023 - 10:28pm | 541Jessica Simpson has refuted rumors suggesting that her significant weight loss was due to the controversial diabetes drug, Ozempic, NZ Herald reports. Denial of Ozempic Use In an interview with Bustle, Simpson denied using Ozempic, a drug known for its weight loss-inducing tendencies and popularity...